Discordance in prediction for prognosis of type 2 diabetes after metabolic surgery: comparison of the ABCD, DiaRem, and individualized metabolic surgery models

Jane Ha1,2,*, Yeongkeun Kwon2,3,*, Nam Hoon Kim2,4, Sungsoo Park2,5, Emanuele Lo Menzo6, Raul J. Rosenthal6

1Department of Medicine, Korea University College of Medicine, Seoul, Korea
2Center for Obesity and Metabolic Diseases, Korea University Anam Hospital, Seoul, Korea
3Department of Family Medicine, Korea University College of Medicine, Seoul, Korea
4Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
5Division of Foregut Surgery, Department of Surgery, Korea University College of Medicine, Seoul, Korea
6Bariatric and Metabolic Institute, Section of Minimally Invasive Surgery, Cleveland Clinic Florida, Weston, FL, USA

Purpose: Metabolic surgery has been performed as a treatment option for uncontrolled type 2 diabetes (T2D), and several scoring systems for predicting postoperative T2D remission have been proposed. This study was designed to assess consistency of 3 existing scoring systems in patients with T2D duration <1 year.

Methods: This study included 186 patients with T2D enrolled in a university hospital prospective database between 2011 and 2013. Externally validated scoring systems for predicting T2D prognosis after metabolic surgery were identified and selected through systematic literature search. We assessed concordance between ABCD, DiaRem, and individualized metabolic surgery (IMS) scores in participants using kappa statistical analysis and 1-way analysis of variance.

Results: Of the participants, 52 and 82 patients were expected to have favorable T2D remission after metabolic surgery with ABCD score of 10–5 and DiaRem score of 0–7, respectively, and a slight-to-fair concordance was shown between the 2 scoring systems (kappa measure, 0.07; standard error [SE], 0.05 and kappa measure, 0.25; SE, 0.19, respectively). The DiaRem score increased with T2D severity determined by IMS score (P < 0.001), while the ABCD score showed no significant association with IMS score.

Conclusion: ABCD and DiaRem scores showed significant discordance when applied to potential metabolic surgery candidates in whom postoperative T2D remission rate was highly expected. The IMS score showed a dose-response association with DiaRem score but had no significant association with the ABCD score.

Key Words: Bariatric surgery, Prognosis, Scores, Type 2 diabetes mellitus

INTRODUCTION

Metabolic surgery has been considered as an option to treat obese individuals with uncontrolled type 2 diabetes (T2D) [1-3]. Both Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) yield significant metabolic outcomes in patients with body mass index (BMI) >35 kg/m2, resulting in T2D remission rates of 50–70% [4-6]. Metabolic surgery for patients with BMI of

*Jane Ha and Yeongkeun Kwon contributed equally to this study as co-first authors.

Copyright © 2019, the Korean Surgical Society

彰宣大學治療研究是開放存取期刊。所有文章按照Creative Commons Attribution Non-Commercial License（http://creativecommons.org/licenses/by-nc/4.0/）发布，允许非商业使用、分发和在任何媒介上以任何方式再发布，但必须以适当方式引用原作。
25–35 kg/m\(^2\) also led to T2D resolution [7,8], and it has been shown to be more effective than medication treatment with respect to T2D remission [2,3,6]; however, metabolic surgery is more effective in patients with BMI >35 kg/m\(^2\). Therefore, the selection of candidates for metabolic surgery with highly expected T2D remission rates is crucial, especially for patients with BMI <35 kg/m\(^2\) that are considering metabolic surgery for uncontrolled T2D.

Several international and government organizations have recently suggested expanding the indications for metabolic surgery to include patients with uncontrolled T2D patients with BMIs as low as 30 kg/m\(^2\) (27.5 kg/m\(^2\) for the Asians) [9-12]. However, current guidelines do not provide selection criteria for patients who have a higher chance of T2D remission after metabolic surgery. While a few scoring systems [13-15] for predicting T2D prognosis after metabolic surgery have been

![Distribution of ABCD, DiaRem, and individualized metabolic surgery (IMS) scores in all participants.](image)

Fig. 1. Distribution of ABCD, DiaRem, and individualized metabolic surgery (IMS) scores in all participants. The total score of each scoring system is calculated by adding the points for each of the 4 variables (left panel). The cutoff values for each variable are shown. A, B, and C in the right panel indicate distribution of ABCD, DiaRem, and IMS scores in all participants, respectively. Intervals are 1 in ABCD score (A), 1 in DiaRem score (B), and 10 in IMS score (C). Subgroups with highly expected diabetes remission (>67%) are marked in panels A and B. BMI, body mass index; T2D, type 2 diabetes; SG, sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass.
developed and mainly validated on the basis of patients with mean BMI >35 kg/m² [7,14,16], considerable disagreement among models was disclosed [17,18]. These reports evoke concerns about applying current prediction models to select metabolic surgery candidates based on expected T2D remission rate. However, there are few reports on the distribution of metabolic surgery candidates’ scores calculated by existing scoring systems and consistency in prognosis prediction in individual patients using different scoring systems.

This study aimed (1) to determine scoring systems for predicting T2D remission rates after RYGB and SG that have been externally validated, and (2) to apply these scoring systems to potential metabolic surgery candidates diagnosed with T2D within a year, and compare expected remission rates calculated by each scoring system.

**METHODS**

**Study population**

We retrospectively reviewed the medical records of patients with T2D in the prospectively collected database initiated in 2011 in Korea University Anam Hospital. The inclusion criteria were diagnosis of T2D and outpatient clinic visit in our hospital between 2011 and 2013 and T2D duration of less than 1 year. The exclusion criteria were (1) type 1 diabetes; (2) age below 19 years; (3) pregnancy or breastfeeding; (4) glucocorticoid use; (5) previous surgery of the stomach, bile duct, pancreas, or large intestine (except hemorrhoidectomy, herniorrhaphy, and appendectomy); (6) transplantation history; (7) diabetes due to pancreatic lesions such as chronic pancreatitis or pancreatic cancer; and (8) diagnosis of cancer except basal cell carcinoma of the skin and carcinoma in situ (patients with disease-free survival longer than 5 years were included). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee. The Institutional Review Board of Korea University Anam Hospital approved (IRB No. 2019AN00058). Written consents were waived by the committee.

**Scoring systems for prediction of diabetes remission after metabolic surgery**

To identify scoring systems developed for prediction of T2D prognosis after metabolic surgery, we analyzed published scientific literature with a structured search strategy. We used MEDLINE and Embase database, and search terms were adapted according to the syntax of each specific database. Main keywords used for the search were “bariatric surgery,” “metabolic surgery,” “Roux-en-Y gastric bypass,” “sleeve gastrectomy,” and “type 2 diabetes.” Scoring systems were selected for this study if (1) they tried to predict the prognosis of T2D after RYGB or SG (other surgical techniques were not considered), (2) they presented an organized protocol (e.g., scoring system or Table 1. Patients characteristics

| Variable                        | Overall (n = 186) | BMI 27.5–32.5 kg/m² (n = 48) |
|--------------------------------|------------------|-----------------------------|
| Age (yr)                       | 54.8 ± 11.7      | 52.6 ± 9.8                  |
| Female sex                     | 73 (39.3)        | 22 (45.8)                   |
| BMI (kg/m²)                    | 25.6 ± 3.9       | 29.2 ± 1.4                  |
| Waist circumference (cm)       | 87.5 ± 12.5      | 93.8 ± 15.2                 |
| Glycated hemoglobin (%)        | 9.1 ± 2.3        | 8.2 ± 1.9                   |
| Fasting plasma glucose (mg/dL) | 166.5 ± 63.5     | 151.5 ± 55.9                |
| 2-Hr postprandial plasma glucose (mg/dL) | 247.9 ± 104.6 | 223.2 ± 108.7 |
| Fasting plasma C-peptide (ng/mL) | 2.1 ± 1.1 | 2.6 ± 1.2                  |
| 2-Hr postprandial plasma C-peptide (ng/mL) | 6.1 ± 3.6 | 7.6 ± 3.7                  |
| Insulin use                     | 36 (19.4)        | 5 (10.4)                    |
| HOMA-IR                         | 3.7 ± 2.6        | 4.6 ± 2.4                   |
| Total cholesterol (mg/dL)       | 184.6 ± 45.6     | 184.3 ± 52.1                |
| Scores calculated by prediction models |                     |                             |
| ABCD score [13]                | 4.1 ± 1.2        | 5.1 ± 1.0                   |
| DiaRem score [14]              | 9.9 ± 5.6        | 7.8 ± 5.0                   |
| IMS score [15]                 | 45.6 ± 23.6      | 48.8 ± 27.0                 |

Values are presented as mean ± standard deviation or number (%).

The mean homeostatic model assessment of insulin resistance represents the product of glucose and insulin concentrations divided by a factor.

BMI, body mass index; HOMA-IR, homeostasis model assessment-insulin resistance; IMS, individualized metabolic surgery.

* Expected diabetes remission rates are 39.8% and 67.7%, respectively.

* Expected diabetes remission rates are 43.5%.

* Expected diabetes remission rate is 60%–70% after Roux-en-Y gastric bypass and 25%–56% after sleeve gastrectomy.
We adopted 3 systems based on the search results: ABCD score [13, 17], DiaRem score [14], and individualized metabolic surgery (IMS) score [15]. Patients with higher ABCD scores were predicted to have a higher probability of T2D remission after surgery. Patients with lower DiaRem scores were predicted to have a higher probability of T2D remission after surgery. IMS score classified diabetes severity into mild, moderate, and severe, and patients with mild diabetes were predicted to have a higher probability of T2D remission after metabolic surgery. Each scoring system is presented in Fig. 1.

OUTCOME ASSESSMENTS

Based on the calculated scores for each patient, we compared (1) the probability of T2D remission according to the scoring systems, (2) difference in patient characteristics by categories of score, (3) patient characteristics between groups wherein postoperative T2D remission was highly expected (expected remission rate > 67% based on ABCD and DiaRem score) were compared, and (4) test agreements of scoring systems in all study populations and patients with BMI of 27.5–32.5 kg/m².

Statistical methods

Data were presented as percentages for categorical variables and means with standard deviations (SDs) for continuous variables. Patient groups by IMS scores (mild, moderate, or severe) were compared using 1-way analysis of variance with Bonferroni post hoc test. Cohen’s kappa statistic was used to assess the level of agreement between the ABCD and DiaRem systems in all participants or those with BMI of 27.5–32.5 kg/m². The a priori level of statistical significance was set at P-value < 0.05 for all analyses; these analyses were 2-tailed and performed using Stata version 12.0 (StataCorp LP, College Station, TX, USA).

RESULTS

Patient characteristics

A total of 186 patients with T2D duration of less than 1 year were included in the analysis (Table 1). Overall, the mean ABCD and DiaRem scores were 4.1 (SD, 1.2) and 9.9 (SD, 5.6), which indicate T2D remission rates of 39.8% and 43.5%, respectively [17]. The mean IMS score was 45.6 (SD, 23.6), which indicates moderate severity. Compared to all study populations, patients with BMI between 27.5 and 32.5 kg/m² showed higher ABCD and IMS scores and lower DiaRem score on average.

Distribution of ABCD, DiaRem, and IMS scores is shown in Fig. 1A, B, and C, respectively.

Table 2. Patient characteristics by categories of ABCD and DiaRem scores

| Score | No. (%) | Age (yr) | Female sex (%) | BMI (kg/m²) | Waist circumference (cm) | Glycated hemoglobin (%) | Fasting plasma glucose (mg/dL) | Fasting plasma C-peptide (ng/mL) | Insulin use, n (%) | HOMA-IR | Total cholesterol (mg/dL) |
|-------|---------|----------|----------------|-------------|--------------------------|------------------------|-------------------------------|---------------------------|----------------|---------|--------------------------|
| ABCD  |         |          |                |             |                         |                        |                               |                           |                 |         |                          |
| 10–9  | 1 (0.5) | 38 ± NA  | 0.0            | 50.5        | 170                     | 6.9                    | 121                           | 5.3                       | 0 (0)          | 8.4     | NA                       |
| 8–7   | 5 (2.7) | 48.4 ± 20.4 | 20.0          | 32.4 ± 4.7  | 106.9 ± 10.2            | 8.8 ± 2.9              | 199 ± 116.1                  | 4.9 ± 0.9                 | 2 (40.0)       | 13.2 ± 7.7 | 224.0 ± 77.8          |
| 6–5   | 46 (24.7) | 53.5 ± 11.9 | 45.7          | 27.8 ± 3.1  | 90.5 ± 16.2             | 8.6 ± 2.0              | 156.6 ± 57.3                 | 3.2 ± 1.0                 | 6 (13.0)       | 4.6 ± 2.2 | 182.7 ± 46.9          |
| 4–3   | 134 (72.0) | 55.6 ± 11.2 | 38.1          | 24.4 ± 2.7  | 85.3 ± 7.2              | 9.2 ± 2.4              | 169.0 ± 63.3                  | 1.7 ± 0.6                 | 28 (20.9)      | 3.1 ± 1.9 | 183.7 ± 43.5          |
| 2–0   | 0 (0)   | NA       | NA             | NA          | NA                      | NA                     | NA                            | NA                        | NA              | NA      | NA                       |
| DiaRem|         |          |                |             |                         |                        |                               |                           |                 |         |                          |
| 0–2   | 8 (4.3) | 45.3 ± 8.8 | 25.0           | 30.1 ± 8.7  | 102.1 ± 28.2            | 6.4 ± 0.3              | 115.5 ± 10.9                  | 3.0 ± 1.6                 | 0 (0)          | 3.3 ± 2.3 | 166.5 ± 25.5          |
| 3–7   | 74 (39.8) | 55.7 ± 11.9 | 40.5          | 26.0 ± 3.2  | 87.7 ± 13.2             | 7.5 ± 1.3              | 136.7 ± 31.3                 | 2.3 ± 1.1                 | 0 (0)          | 3.5 ± 1.8 | 191.1 ± 50.3          |
| 8–12  | 50 (31.2) | 56.7 ± 9.7 | 50.0          | 25.0 ± 3.3  | 86.2 ± 8.3              | 9.6 ± 1.7              | 168.7 ± 55.2                  | 2.1 ± 1.0                 | 0 (0)          | 3.5 ± 1.9 | 174.1 ± 35.2          |
| 13–17 | 15 (8.1) | 41.9 ± 13.8 | 26.7          | 26.2 ± 4.7  | 87.7 ± 13.7             | 11.2 ± 2.7             | 215.9 ± 88.6                  | 1.3 ± 0.9                 | 11 (73.3)      | 3.2 ± 2.4 | 194.7 ± 41.9          |
| 18–22 | 31 (16.7) | 57.9 ± 9.2 | 25.8          | 24.1 ± 3.2  | 85.7 ± 8.2              | 11.5 ± 1.5             | 224.6 ± 74.3                  | 1.9 ± 0.9                 | 25 (80.7)      | 5.0 ± 4.5 | 186.8 ± 53.2          |

Values are presented as mean ± standard deviation unless otherwise indicated.

BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; NA, not applicable.
| Variable                        | Overall | BMI 27.5–32.5 kg/m² |
|--------------------------------|---------|---------------------|
|                                | ABCD score 10–5 (n = 52) | DiaRem score 0–7 (n = 82) | ABCD score 10–7 (n = 34) | DiaRem score 0–7 (n = 27) |
| Age (yr)                       | 52.7 ± 12.8 | 54.6 ± 12.0 | 51.3 ± 10.0 | 51.3 ± 9.8 |
| Female sex                     | 22 (42.3) | 32 (39.0) | 14 (41.2) | 13 (48.2) |
| BMI (kg/m²)                    | 28.7 ± 4.7 | 26.4 ± 4.1 | 29.3 ± 1.4 | 29.3 ± 1.4 |
| Waist circumference (cm)       | 93.4 ± 19.6 | 89.1 ± 15.6 | 93.5 ± 17.9 | 91.8 ± 19.4 |
| Glycated hemoglobin (%)        | 8.6 ± 2.0 | 7.4 ± 1.3 | 8.1 ± 1.8 | 7.4 ± 1.6 |
| Fasting plasma glucose (mg/dL) | 160.0 ± 64.4 | 134.7 ± 30.6 | 154.5 ± 54.0 | 140.3 ± 44.4 |
| Postprandial plasma glucose    | 237.8 ± 105.2 | 198.1 ± 65.8 | 226.9 ± 110.3 | 189.2 ± 80.5 |
| (mg/dL)                        |          |          |          |          |
| Fasting plasma C-peptide (ng/mL)| 3.8 ± 1.1 | 2.4 ± 1.2 | 3.1 ± 1.0 | 2.7 ± 1.2 |
| Postprandial plasma C-peptide  | 8.9 ± 3.9 | 7.8 ± 3.6 | 8.7 ± 3.6 | 8.3 ± 4.2 |
| (ng/mL)                        |          |          |          |          |
| Insulin use                    | 0 (0)   | 0 (0)    | 0 (0)    | 0 (0)    |
| HOMA-IR                        | 5.4 ± 3.6 | 3.4 ± 1.8 | 5.1 ± 2.5 | 4.3 ± 2.1 |
| Total cholesterol (mg/dL)      | 187.0 ± 51.4 | 189.2 ± 49.2 | 188.7 ± 53.7 | 191.3 ± 53.3 |

Scores calculated by other systems: 8.2 ± 4.9 (calculated by DiaRem)\(^a\), 4.3 ± 1.3 (calculated by ABCD)\(^b\), 7.0 ± 4.0 (calculated by DiaRem)\(^c\), 5.3 ± 1.1 (calculated by ABCD)\(^d\)

Distribution of scores calculated by other systems:

| Categories by DiaRem scores | Overall | BMI 27.5–32.5 kg/m² |
|-----------------------------|---------|---------------------|
| 0–2                         | 5 (9.6) | 4 (11.8)            |
| 3–7                         | 23 (44.2) | 16 (47.1)         |
| 8–12                        | 16 (30.8) | 12 (35.3)         |
| 13–17                       | 3 (5.8)  | 1 (2.9)             |
| 18–22                       | 5 (9.6)  | 1 (2.9)             |

Kappa (SE)\(^e\):

| Overall | BMI 27.5–32.5 kg/m² |
|---------|---------------------|
| 0.07 ± 0.05 | 0.08 ± 0.07       |

| Categories by ABCD scores | Overall | BMI 27.5–32.5 kg/m² |
|---------------------------|---------|---------------------|
| 10–9                      | 1 (1.2) | 0 (0)               |
| 8–7                       | 3 (3.7) | 3 (11.1)            |
| 6–5                       | 24 (29.3)| 17 (63.0)           |
| 4–3                       | 54 (65.9)| 7 (25.9)            |
| 2–0                       | 0 (0)   | 0 (0)               |

Kappa (SE)\(^e\):

|                | Overall | BMI 27.5–32.5 kg/m² |
|----------------|---------|---------------------|
|                | 0.003 ± 0.007 | -0.02 ± 0.02         |

Values are presented as mean ± standard deviation or number (%).

BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; SE, standard error; NA, not applicable.

\(^a\) Expected diabetes remission rates are 43.5% and 39.8%, respectively [17].

\(^b\) Expected diabetes remission rates are 85.3% and 67.7%, respectively.

\(^e\) Measure of agreement: <0 (poor), 0.0–0.2 (slight), 0.21–0.40 (fair), 0.41–0.60 (moderate), 0.61–0.80 (substantial), and 0.81–1.0 (almost perfect).
Patient characteristics by categories of ABCD and DiaRem scores

Table 2 shows outcomes of patients assigned into 5 categories based on calculated ABCD and DiaRem scores. Patients with higher ABCD scores were younger on average while there was no consistent tendency between DiaRem score and age. The mean BMI gradually decreased with decreasing ABCD score but showed no consistent tendency with DiaRem scores. Patients with higher DiaRem scores showed higher glycated hemoglobin level, and those with lower ABCD scores showed lower C-peptide level.

Comparison between patients with high expected diabetes remission rate

Outcomes of patients whose scores indicated highly expected diabetes remission (ABCD score, 10–5; DiaRem score, 0–7) are described in Table 3. In patients whose ABCD score was between 10 and 5, Cohen kappa showed slight concordance between 2 scoring systems (0.07; SE, 0.05). Patients whose DiaRem score was between 0 and 7 demonstrated slight concordance between the 2 scoring systems (0.003; SE, 0.007). Kappa measures represented poor to slight agreement in the analysis of patients with BMI 27.5–32.5 kg/m² (0.08 and -0.02; SE, 0.02). Fig. 2 shows distribution of DiaRem (Fig. 2A) and ABCD (Fig. 2B) scores, among patients in whom diabetes remission was highly expected according to the other system.

Comparison by categories of IMS scoring system

IMS scores were calculated, and patients were divided into 3 categories (Table 4). The mean DiaRem scores of the mild (6.7 ± 6.1), moderate (10.3 ± 5.2), and severe (16.2 ± 5.8) groups were significantly different from each other. Consistently, the analysis of patients with BMI between 27.5 and 32.5 kg/m² showed that the DiaRem score increased as IMS score moved from mild to severe. Post hoc tests were not performed for the subgroup because the severe group had less than 2 cases. The ABCD score showed no association with IMS score.

DISCUSSION

The new guidelines from American Diabetes Association recommends metabolic surgery to treat T2D in surgical candidates with BMI ≥40 kg/m² (BMI ≥37.5 kg/m² in the Asian-American population), regardless of the glycemic control level or complexity of glucose-lowering regimens, and in adults with BMI of 35.0–39.9 kg/m² (32.5–37.4 kg/m² in the Asian-American population) when hyperglycemia is inadequately controlled despite lifestyle and optimal medical therapy [19]. Moreover, adults with T2D and BMI of 30.0–34.9 kg/m² (27.5–32.4 kg/m² in the Asian-American population) should consider metabolic surgery if hyperglycemia is inadequately controlled despite optimal medical control by either oral and injectable medications [19]. Even though the remission rate is not confirmed yet and unsuccessful outcome after metabolic surgeries needs to be considered, selection criteria of candidates undergoing metabolic surgery in current metabolic surgery guidelines are not mentioned [19-21]. Prediction of patients with higher chance of T2D remission after surgery is necessary, and some scoring systems are required to help select and consult such patients in clinical practice.

Existing scoring systems are not sufficiently validated in various ethnicities and BMI ranges. The ABCD score [13] was developed by analysis of Asian populations with BMI of 36.5 kg/m², while the DiaRem [14] and IMS scores [15] were developed based...
Table 4. Application of the individualized metabolic surgery (IMS) score system

| Variable                                      | Overall Categories by IMS score | BMI, 27.5–32.5 kg/m² Categories by IMS score | P-value | P-value |
|-----------------------------------------------|---------------------------------|-----------------------------------------------|---------|---------|
|                                | Mild (n = 29) | Moderate (n = 152) | Severe (n = 5) | Mild (n = 8) | Moderate (n = 39) | Severe (n = 1) |
| Age (yr)                                      | 51.6 ± 11.8 | 55.3 ± 11.6 | 57.4 ± 12.5 | 0.246 | 48 ± 10.9 | 53.1 ± 9.4 | 63 | 0.227 |
| Female sex                                    | 8 (27.6) | 63 (41.5) | 2 (40.0) | 0.379 | 2 (25.0) | 20 (51.3) | 0 (0) | 0.270 |
| BMI (kg/m²)                                   | 26.1 ± 5.5 | 25.5 ± 3.5 | 25.4 ± 3.0 | 0.690 | 28.8 ± 1.2 | 29.3 ± 1.4 | 29.3 | 0.615 |
| Waist circumference (cm)                      | 90.5 ± 17.4 | 87.1 ± 11.5 | 83.6 ± 4.0 | 0.337 | 94.7 ± 5.4 | 93.8 ± 16.6 | 90 | 0.959 |
| Glycated hemoglobin (%)                       | 7.8 ± 2.4 | 9.2 ± 2.2 | 11 ± 2.1 | 0.001 | 6.5 ± 0.3 | 8.5 ± 1.8 | 10.7 | 0.006 |
| Fasting plasma glucose (mg/dL)                | 143.1 ± 48.1 | 170.8 ± 64.3 | 169 ± 96.4 | 0.106 | 116.3 ± 15.9 | 160.2 ± 58.5 | 102 | 0.084 |
| 2-Hr postprandial plasma glucose (mg/dL)      | 204.3 ± 100.5 | 255.9 ± 104.1 | 258.5 ± 99.5 | 0.055 | 130.5 ± 40.6 | 243.2 ± 108.6 | NA | 0.006 |
| Fasting plasma C-peptide (ng/mL)              | 2.2 ± 1.5 | 2.1 ± 1.0 | 1.9 ± 0.4 | 0.822 | 2.8 ± 1.7 | 2.6 ± 1.0 | 1.4 | 0.546 |
| 2-Hr postprandial plasma C-peptide (ng/mL)    | 6.7 ± 4.1 | 6.0 ± 3.4 | 5.4 ± 4.8 | 0.552 | 8.3 ± 5.1 | 7.7 ± 3.4 | 1.9 | 0.272 |
| Insulin use                                   | 0 (0) | 33 (21.7) | 3 (60.0) | 0.002 | 0 (0) | 4 (10.3) | 1 (100) | 0.007 |
| HOMA-IR                                       | 2.8 ± 1.7 | 3.9 ± 2.8 | 2.6 ± 1.3 | 0.121 | 2.0 ± 0.5 | 5.0 ± 2.4 | 1.7 | 0.028 |
| Total cholesterol (mg/dL)                     | 187.8 ± 33.5 | 184.4 ± 46.8 | 171.8 ± 69.4 | 0.773 | 168.9 ± 33.9 | 189.8 ± 52.9 | 89 | 0.112 |
| ABCD score                                    | 4.3 ± 1.8 | 4.0 ± 1.1 | 3.8 ± 0.8 | 0.516 | 5.6 ± 1.4 | 5.1 ± 0.8 | 4 | 0.152 |
| DiaRem score                                  | 6.7 ± 6.1 | 10.3 ± 5.2 | 16.2 ± 5.8 | <0.001 | 2.4 ± 2.1 | 8.6 ± 4.2 | 22 | <0.001 |

Values are presented as mean ± standard deviation or number (%).
BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance.
The P-value was calculated by 1-way analysis of variance.
Mild stage: RYGB is recommended, and the expected remission rate after RYGB is 92%. Severe stage: Expected remission rates after both RYGB and SG are less than 15%. SG is recommended with expected remission rate of 12%. Moderate stage: RYGB is recommended, and the expected remission rate is 60%. The mean difference is significant at the 0.05 level.
on American populations with mean BMI >45 kg/m². This difference must be thoroughly assessed since the Asian population is more likely to develop T2D in younger age with lower BMI compared to the Caucasian population [22,23]. Moreover, a preceding study showed that only 25% of non-obese patients with T2D (mean BMI, 26.9 kg/m²) had remission after surgery while patients with higher BMI (mean BMI, 49.5 kg/m²) showed a remission of 79% [24]. This result implies the impact of baseline BMI on T2D remission rate, and evaluation of these systems on non-obese metabolic surgery candidates is imperative.

All patients obtained 3 out of 3 points for T2D duration since they had T2D for less than 1 year. Most patients got poor score for age since the cutoff was 40 years while the mean age of patients was 54.8 years. Therefore, the ABCD score was particularly dependent on C-peptide level and BMI. Besides the 3 points for T2D duration, patients obtained 1.3 out of 7 points on average. The ABCD score was adjusted downward and was not useful in stratifying patients according to the expected remission rates.

The distribution of DiaRem score was wider than that of ABCD score. The impact of insulin treatment on DiaRem score (10 of 22 points) was the largest among the 4 factors. According to the guidelines for T2D in Korea [25], a glycated hemoglobin level >9.0% during diagnosis is an indication for insulin treatment and oral hypoglycemic agent combination therapy. Thus, a glycated hemoglobin level >9.0% directly affects the DiaRem score with respect to insulin treatment and use of combination drugs, as well as glycated hemoglobin level itself. Glycated hemoglobin level showed high correlation to the DiaRem score (Table 2) and contributed to the DiaRem score’s wide distribution.

According to previous studies, the DiaRem score was useful to predict T2D remission in those with a low DiaRem score but more limited in its predictive power in those with a high DiaRem score [17,26] while the ABCD score was relatively more accurate throughout a wider range [17]. Accordingly, when each scoring system was applied to patients with T2D (BMI, 35.7 ± 7.8 kg/m²), the distribution of high ABCD and low DiaRem scores were similar [17]. However, no correlation between the ABCD and DiaRem scores was noted in the whole range, and disagreement between these scoring systems was also significant when they were applied to participants with highly expected T2D remission (Table 3, Fig. 2). These inconsistencies warrant further analysis of an existing scoring system in different ethnic groups and BMI ranges.

The IMS score categorizes patients into 3 stages of diabetes severity and T2D remission rate is expected to be higher in patients with mild severity [15]. We observed a dose-response association between mean DiaRem score and IMS score stage, while there was no significant difference in ABCD scores between each stage (Table 4). Both DiaRem and IMS scoring systems were developed in Caucasian populations with class 3 obesity (mean BMI, 49.4 and 46.4 kg/m², respectively), while the ABCD scoring system was first introduced in Asian populations. This explains the disagreement between results in different ethnicities and BMI ranges and indicates insufficient evidence to utilize existing scoring systems in an unverified range of BMI or ethnic group.

The study had some limitations. First, this study was conducted with a cohort of patients who had T2D for less than 1 year, not with actual metabolic surgery candidates. Considering that most previous studies were performed on patients with T2D who were expected to undergo metabolic surgeries, there might be some inconsistencies derived from different cohort characteristics. Nevertheless, scoring systems for predicting metabolic surgery need to be applied to not only metabolic surgery candidates but also patients with T2D considering the expected remission rate in decision making. Second, this study could not determine the scoring system with highest accuracy for predicting T2D remission rate due to lack of postoperative data. Still, discordance between the scoring systems applied to potential metabolic surgery candidates implies inadequacies of selecting candidates for surgery by current scoring systems. Third, there were possible unknown confounders due to its retrospective and nonrandomized design. Fourth, the study population included Korean adults who have limited diversity in ethnicity, and the patient characteristics might have been biased. Lastly, expected remission rates were not verified in diverse groups, and we adopted a remission rate calculated in a cohort of 245 Asian patients with T2D who underwent metabolic surgery [16]. We evaluate the expected remission rates observed in a group of patients with the same ethnicity and BMI range to improve accuracy.

We observed considerable discordance between T2D remission rate predicted by ABCD and DiaRem scores in patients with T2D duration of less than a year. The result was consistent in the subgroup with BMI of 27.5 to 32.5 kg/m². The IMS score showed a dose-response association with the DiaRem score, which was developed in study populations with the same ethnicity and BMI range, but there was no significant association between IMS and ABCD scores, which was developed in different ethnicities with different degrees of obesity.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge Sohui Lee (Korea...
REFERENCES

1. Dixon JB, Zimmet P, Alberti KG, Rubino F. International Diabetes Federation Task-force on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med 2011;28:628-42.

2. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-85.

3. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothers CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-76.

4. Helmio M, Victorzon M, Ovaska J, Leivonen M, Juuti A, Peromaa-Haavisto P, et al. Comparison of short-term outcome of laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: a prospective randomized controlled multicenter SLEEVEPASS study with 6-month follow-up. Scand J Surg 2014;103:175-81.

5. Peterli R, Wolnerhanssen BK, Vetter D, Nett P, Gass M, Bobely Y, et al. Laparoscopic sleeve gastrectomy versus Roux-Y Gastric bypass for morbid obesity-3-year outcomes of the prospective randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg 2017;265:466-73.

6. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014;370:2002-13.

7. Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Lee YC. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg 2012;16:45-51.

8. Huang CK, Shabbir A, Lo CH, Tai CM, Chen YS, Houng YJ. Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25-35. Obes Surg 2011;21:1344-9.

9. Rubino F, Kaplan LM, Schauer PR, Cummings DE. Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010;251:399-405.

10. Cummings DE, Cohen BV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2014;2:175-81.

11. Zimmert P, Alberti KG, Rubino F, Dixon JB. IDF’s view of bariatric surgery in type 2 diabetes. Lancet 2011;378:108-10.

12. Kasama K, Mui W, Lee WJ, Lakdawala M, Naitoh T, Seki Y, et al. IFSO-APC consensus statements 2011. Obes Surg 2012;22:677-84.

13. Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Chen SC, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Obes Surg 2013;23:379-84.

14. Still CD, Wood GC, Benotti P, Petrick AT, Gabrielsen J, Strodel WE, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2014;2:38-45.

15. Aminian A, Brethauer SA, Andalib A, Nowacki AS, Jimenez A, Corcelles R, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg 2017;266:650-7.

16. Lee WJ, Almulaifi A, Tsou JJ, Ser KH, Lee YC, Chen SC. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus: predicting the success by ABCD score. Obes Surg Relat Dis 2015;11:991-6.

17. Lee WJ, Chong K, Chen SC, Zachariah J, Ser KH, Lee YC, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg 2016;26:2418-24.

18. Ahuja A, Tantia O, Chaudhuri TH, Khanna S, Seetharamaiah S, Majumdar K, et al. Predicting remission of diabetes post metabolic surgery: a comparison of ABCD, diarem, and DRS scores. Obes Surg 2018; 28:2025-31.

19. American Diabetes Association. 7. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018; 41(Suppl 1):S65-72.

20. Korean Society for Metabolic and Bariatric Surgery. 2018 Korean Society for Metabolic and Bariatric Surgery Guidelines. J Metab Bariatr Surg 2018;7:1-21.

21. Fried M, Yumuk V, Oppert JM, Scopinaro N, Torres AJ, Weiner R, et al. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts 2013;6:449-68.

22. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40.

23. Araneta MR, Wingard DL, Barrett-Connor E. Type 2 diabetes and metabolic syndrome in Filipina-American women: a high-risk nonobese population. Diabetes Care 2002;25:494-9.

24. Lee WJ, Almulaifi A, Chong K, Chen SC, Tsou JJ, Ser KH, et al. The effect and predictive score of gastric bypass and sleeve gastrectomy on type 2 diabetes mellitus patients with BMI <30 kg/m². Obes Surg 2015;25:1772-8.
25. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, et al. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011;35:431-6.

26. Tharakan G, Scott R, Szepietowski O, Miras AD, Blakemore AI, Purkayastha S, et al. Limitations of the DiaRem score in predicting remission of diabetes following Roux-En-Y Gastric Bypass (RYGB) in an ethnically diverse population from a single institution in the UK. Obes Surg 2017;27:782-6.